Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(23):1734-1735; doi:10.1093/jnci/96.23.1734
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vanchieri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanchieri, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Vioxx Withdrawal Alarms Cancer Prevention Researchers

Cori Vanchieri

The first 150 words of the full text of this article appear below.

Thanks to a colon cancer prevention study, millions of arthritis sufferers lost a favorite pain reliever. Is that good news or bad? Good news certainly for the patients who no longer face unreasonable risks for heart attack and stroke; bad news, potentially, if the Vioxx debacle drains the chemoprevention drug pipeline.

The study isn't the first to reveal side effects of a promising chemoprevention agent, and it probably won't be the last. Cancer researchers are eager to point out, however, that many approved drugs carry some risks and that the Vioxx case should not deter researchers and pharmaceutical companies from doing the long-term studies needed to show chemopreventive effects.

When Merck withdrew Vioxx (rofecoxib) from the market on September 30, concerns were for arthritis sufferers, the main users of the drug. But the study that showed the increased risk of heart attack and stroke among Vioxx users was a Merck-funded . . . [Full Text of this Article]

A Familiar Road

Risk Is Relative

Different Strategies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
L. Yu, W. K. K. Wu, Z. J. Li, H. P. S. Wong, E. K. K. Tai, H. T. Li, Y. C. Wu, and C. H. Cho
E Series of Prostaglandin Receptor 2-Mediated Activation of Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Is Required for the Mitogenic Action of Prostaglandin E2 in Esophageal Squamous-Cell Carcinoma
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 258 - 267.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. de Leval, T. Dassesse, J.-M. Dogne, D. Waltregny, A. Bellahcene, V. Benoit, B. Pirotte, and V. Castronovo
Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1057 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
D. M. Olson
The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?
Reproductive Sciences, October 1, 2005; 12(7): 466 - 478.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
C. Han and T. Wu
Cyclooxygenase-2-derived Prostaglandin E2 Promotes Human Cholangiocarcinoma Cell Growth and Invasion through EP1 Receptor-mediated Activation of the Epidermal Growth Factor Receptor and Akt
J. Biol. Chem., June 24, 2005; 280(25): 24053 - 24063.
[Abstract] [Full Text] [PDF]